We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Acorda Therapeutics Inc (ACORQ) USD0.001

Sell:$0.0735 Buy:$0.0735 Change: $0.0315 (30.00%)
Market closed |  Prices as at close on 26 July 2024 | Switch to live prices |
Sell:$0.0735
Buy:$0.0735
Change: $0.0315 (30.00%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 26 July 2024 | Switch to live prices |
Sell:$0.0735
Buy:$0.0735
Change: $0.0315 (30.00%)
Market closed |  Prices as at close on 26 July 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Acorda Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. The Company markets Inbrija (levodopa inhalation powder), which is approved in the United States for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson’s disease treated with carbidopa/levodopa. Inbrija is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor, such as phenelzine or tranylcypromine within the last two weeks. Inbrija utilizes its ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. ARCUS is a dry-powder pulmonary drug delivery technology. It also markets the branded AMPYRA (dalfampridine) extended-release tablets, 10 mg, to improve walking in adults with multiple sclerosis. Ampyra is marketed as Fampyra outside the United States by Biogen International GmbH.

Contact details

Address:
TWO BLUE HILL PLAZA
PEARL RIVER
10965
United States
Telephone:
+1 (914) 3474300
Website:
https://www.acorda.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ACORQ
ISIN:
US00484M7002
Market cap:
$110,630
Shares in issue:
1.24 million
Sector:
Biotechnology
Exchange:
Off Exchange
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Ron Cohen
    President, Chief Executive Officer, Director
  • Michael Gesser
    Chief Financial Officer, Treasurer
  • Neil Belloff
    General Counsel, Corporate Secretary
  • Kerry Clem
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.